Abstract
Oxatomide (CAS 60607-34-3), a diphenylmethylpiperazine benzimidazole derivative is a new oral antiallergic drug useful in asthma in preventing allergic attacks. Using the model of citric acid-induced coughing in the unanesthetized, unrestrained guinea pig the antitussive effect of oxatomide was investigated. The animals were treated with logarithmically increasing doses of oxatomide (0.5, 1, 2 mg/kg, suspended in 0.5 ml of polyethylene glycol 200 + 0.5 ml of saline) and with the vehicle alone administered intraperitoneally (1 ml) 45 min before the challenge. Oxatomide reduced the number of coughs during the 3 min of challenge, lengthened the time of onset and reduced the number of coughs after cessation of the challenge significantly and a linear dose-effect regression was observed.
Original language | English |
---|---|
Pages (from-to) | 550-553 |
Number of pages | 4 |
Journal | Arzneimittel-Forschung/Drug Research |
Volume | 43 |
Issue number | 5 |
Publication status | Published - 1993 |
Keywords
- antiallergic drugs
- antitussives
- CAS 60607-34-3
- oxatomide, pharmacology
- Tinset®
ASJC Scopus subject areas
- Chemistry(all)
- Organic Chemistry
- Drug Discovery
- Pharmacology